Evidence map›Paper›PMID 42569537›Full record

Trial reportDepression and anxiety2026

High Dose Vitamin B6 Reduces Depression Symptoms.

David T Field, Rebekah Cracknell, Nicolo Biagi

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Depression and anxiety, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

David T FieldSchool of Psychology and Clinical Language Sciences, The University of Reading, Reading, Berkshire, UK, reading.ac.uk.ORCID https://orcid.org/0000-0003-4041-8404
Rebekah CracknellSchool of Psychology and Clinical Language Sciences, The University of Reading, Reading, Berkshire, UK, reading.ac.uk.
Nicolo BiagiSchool of Psychology and Clinical Language Sciences, The University of Reading, Reading, Berkshire, UK, reading.ac.uk.ORCID https://orcid.org/0000-0002-7119-0767

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Several lines of evidence suggest that vitamin B6 has potential as an antidepressant. It plays a crucial coenzyme role in the synthesis of the neurotransmitters serotonin, gamma-aminobutyric acid (GABA) and dopamine, which are central to mood regulation, and it has been shown that increasing availably of vitamin B6 above normal levels increases concentrations of serotonin and GABA. Furthermore, epidemiological evidence points to vitamin B6 deficiency as a risk factor for depression, and to high vitamin B6 levels as protective. Therefore, we asked whether taking 100 mg vitamin B6 as pyridoxine daily for 1 month would reduce depression symptoms, measured with the Depression, Anxiety and Stress Scales (DASS) questionnaire, which also assesses anxiety and stress. Methods: We recruited 267 participants from the general population (215 female) and double blind randomised them to receive either placebo, vitamin B6 or vitamin B12 (1000 µg). Using baseline DASS scores, we divided participants into a group classified as having mild or more severe depression symptoms at baseline ( Results: Only within the former group, vitamin B6 produced a selective reduction in depression symptoms compared to placebo or vitamin B12 with a very large effect size (partial Conclusions: We have shown that high-dose vitamin B6 has therapeutic potential for depression, and large-scale clinical trials with patients should now be conducted to determine whether these findings from our mostly female sample generalise to males, to quantify the dose-response relationship, and to evaluate its potential as an adjunct to existing treatments versus monotherapy, and to elucidate which factors, for example, presence of inflammation, predict responsiveness to the intervention.

Indexed as

DepressionVitamin B 6Vitamin B ComplexAdultDouble-Blind MethodFemaleHumansMaleMiddle AgedPyridoxineTreatment OutcomeVitamin B 12PyridoxineVitamin B 12Vitamin B 6Vitamin B Complexanxietydepressioninflammationpyridoxinestressvitamin B6

Identifiers

PMID42569537
PMCPMC13450120

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.